Hims & Hers Health, Inc. (NYSE:HIMS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMSGet Free Report) have earned an average rating of “Moderate Buy” from the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $20.29.

Several research analysts recently commented on HIMS shares. Jefferies Financial Group increased their price objective on Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, June 27th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and increased their price target for the company from $16.00 to $20.00 in a report on Wednesday, May 22nd. Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Finally, Truist Financial increased their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th.

Read Our Latest Analysis on HIMS

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total transaction of $3,919,426.00. Following the completion of the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $695,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, COO Melissa Baird sold 17,625 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $20.51, for a total value of $361,488.75. Following the completion of the sale, the chief operating officer now directly owns 585,800 shares of the company’s stock, valued at $12,014,758. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $20.75, for a total value of $3,919,426.00. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $695,166.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 753,292 shares of company stock valued at $13,557,329. 17.71% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently modified their holdings of the company. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $86,836,000. Renaissance Technologies LLC lifted its holdings in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares during the period. Farallon Capital Management LLC increased its holdings in shares of Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after purchasing an additional 1,634,000 shares in the last quarter. M&G Plc acquired a new position in Hims & Hers Health during the first quarter worth about $8,232,000. Finally, State of Michigan Retirement System boosted its stake in shares of Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after acquiring an additional 320,000 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Up 5.1 %

HIMS stock opened at $15.27 on Friday. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The company’s 50-day simple moving average is $17.97 and its 200-day simple moving average is $16.92. The firm has a market cap of $3.28 billion, a P/E ratio of -1,527.00 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMSGet Free Report) last announced its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. During the same quarter last year, the business earned ($0.03) earnings per share. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. On average, analysts anticipate that Hims & Hers Health will post 0.22 earnings per share for the current fiscal year.

About Hims & Hers Health

(Get Free Report

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Recommended Stories

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.